Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

High-grade angiosarcoma presenting with cytology-negative hemorrhagic ascites.

Patel AP, Peacock JL, Prieto PA.

J Surg Case Rep. 2018 Oct 11;2018(10):rjy273. doi: 10.1093/jscr/rjy273. eCollection 2018 Oct.

2.

A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma.

Mooradian MJ, Reuben A, Prieto PA, Hazar-Rethinam M, Frederick DT, Nadres B, Piris A, Juneja V, Cooper ZA, Sharpe AH, Corcoran RB, Flaherty KT, Lawrence DP, Wargo JA, Sullivan RJ.

Oncoimmunology. 2018 Feb 1;7(5):e1423172. doi: 10.1080/2162402X.2017.1423172. eCollection 2018.

PMID:
29721378
3.

Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.

Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA.

Lancet Oncol. 2018 Feb;19(2):181-193. doi: 10.1016/S1470-2045(18)30015-9. Epub 2018 Jan 18.

PMID:
29361468
4.

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA.

Science. 2018 Jan 5;359(6371):97-103. doi: 10.1126/science.aan4236. Epub 2017 Nov 2.

5.

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.

Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA.

NPJ Genom Med. 2017;2. pii: 10. doi: 10.1038/s41525-017-0013-8. Epub 2017 Apr 7.

6.

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.

Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA.

Sci Transl Med. 2017 Mar 1;9(379). pii: eaah3560. doi: 10.1126/scitranslmed.aah3560. Erratum in: Sci Transl Med. 2017 Apr 12;9(385):.

7.

Gene Targeting Meets Cell-Based Therapy: Raising the Tail, or Merely a Whimper?

Cogdill AP, Prieto PA, Reuben A, Wargo JA.

Clin Cancer Res. 2017 Jan 15;23(2):327-329. doi: 10.1158/1078-0432.CCR-16-2493. Epub 2016 Nov 11.

8.

Endocrine incidentalomas.

Starker LF, Prieto PA, Liles JS, Tran Cao HS, Grubbs EG, Lee JE, Perrier ND, Graham PH.

Curr Probl Surg. 2016 May;53(5):219-46. doi: 10.1067/j.cpsurg.2016.04.001. Epub 2016 May 3. Review. No abstract available.

PMID:
27325542
9.

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.

Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA.

Cancer Discov. 2016 Aug;6(8):827-37. doi: 10.1158/2159-8290.CD-15-1545. Epub 2016 Jun 14.

10.

Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma.

Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JA.

Oncoimmunology. 2016 Feb 2;5(3):e1136044. eCollection 2016 Mar.

11.

Targeted Therapies Combined With Immune Checkpoint Therapy.

Prieto PA, Reuben A, Cooper ZA, Wargo JA.

Cancer J. 2016 Mar-Apr;22(2):138-46. doi: 10.1097/PPO.0000000000000182. Review.

PMID:
27111910
12.

Cervical hematoma following an endocrine surgical procedure: The MD Anderson experience.

Christakis IA, Potylchansky E, Silva AM, Nates JP, Prieto PA, Graham PH, Grubbs EG, Lee JE, Perrier ND.

Surgery. 2016 Aug;160(2):377-83. doi: 10.1016/j.surg.2016.02.024. Epub 2016 Apr 7.

PMID:
27063343
13.

Direct evidence for the presence of human milk oligosaccharides in the circulation of breastfed infants.

Goehring KC, Kennedy AD, Prieto PA, Buck RH.

PLoS One. 2014 Jul 7;9(7):e101692. doi: 10.1371/journal.pone.0101692. eCollection 2014.

14.

DKK1 as a serum biomarker for hepatocellular carcinoma.

Prieto PA, Cha CH.

Hepatobiliary Surg Nutr. 2013 Jun;2(3):127-8. doi: 10.3978/j.issn.2304-3881.2012.10.12. No abstract available.

15.

2'-fucosyllactose: an abundant, genetically determined soluble glycan present in human milk.

Castanys-Muñoz E, Martin MJ, Prieto PA.

Nutr Rev. 2013 Dec;71(12):773-89. doi: 10.1111/nure.12079. Epub 2013 Nov 18. Review.

16.

ILSI Brazil International Workshop on Functional Foods: a narrative review of the scientific evidence in the area of carbohydrates, microbiome, and health.

Latulippe ME, Meheust A, Augustin L, Benton D, Berčík P, Birkett A, Eldridge AL, Faintuch J, Hoffmann C, Jones JM, Kendall C, Lajolo F, Perdigon G, Prieto PA, Rastall RA, Sievenpiper JL, Slavin J, de Menezes EW.

Food Nutr Res. 2013;57. doi: 10.3402/fnr.v57i0.19214. Epub 2013 Feb 7.

17.

Appendiceal endometriosis in a pregnant woman presenting with acute perforated appendicitis.

Lebastchi AH, Prieto PA, Chen C, Lui FY.

J Surg Case Rep. 2013 Dec 16;2013(12). pii: rjt104. doi: 10.1093/jscr/rjt104.

18.

Profiles of human milk oligosaccharides and production of some human milk oligosaccharides in transgenic animals.

Prieto PA.

Adv Nutr. 2012 May 1;3(3):456S-64S. doi: 10.3945/an.111.001529. Review.

19.

Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes.

Friedman KM, Prieto PA, Devillier LE, Gross CA, Yang JC, Wunderlich JR, Rosenberg SA, Dudley ME.

J Immunother. 2012 Jun;35(5):400-8. doi: 10.1097/CJI.0b013e31825898c5.

PMID:
22576345
20.

Liver directed therapy for renal cell carcinoma.

Langan RC, Ripley RT, Davis JL, Prieto PA, Datrice N, Steinberg SM, Bratslavsky G, Rudloff U, Kammula US, Stojadinovic A, Avital I.

J Cancer. 2012;3:184-90. doi: 10.7150/jca.4456. Epub 2012 Apr 20.

21.

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma.

Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ.

Clin Cancer Res. 2012 Apr 1;18(7):2039-47. doi: 10.1158/1078-0432.CCR-11-1823. Epub 2012 Jan 23.

22.

Assessment of ovarian function after preparative chemotherapy and total body radiation for adoptive cell therapy.

Langan RC, Prieto PA, Sherry RM, Zlott D, Wunderlich J, Csako G, Costello R, White DE, Rosenberg SA, Yang JC.

J Immunother. 2011 May;34(4):397-402. doi: 10.1097/CJI.0b013e3182187508.

23.

CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma.

Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC, Phan GQ, Kammula US, Hughes MS, Citrin DE, Restifo NP, Wunderlich JR, Prieto PA, Hong JJ, Langan RC, Zlott DA, Morton KE, White DE, Laurencot CM, Rosenberg SA.

Clin Cancer Res. 2010 Dec 15;16(24):6122-31. doi: 10.1158/1078-0432.CCR-10-1297. Epub 2010 Jul 28.

24.

Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy.

Prieto PA, Durflinger KH, Wunderlich JR, Rosenberg SA, Dudley ME.

J Immunother. 2010 Jun;33(5):547-56. doi: 10.1097/CJI.0b013e3181d367bd.

PMID:
20463593
25.

Dual infection with hepatitis A and E viruses in outbreaks and in sporadic clinical cases: Cuba 1998-2003.

Rodríguez Lay Lde L, Quintana A, Villalba MC, Lemos G, Corredor MB, Moreno AG, Prieto PA, Guzmán MG, Anderson D.

J Med Virol. 2008 May;80(5):798-802. doi: 10.1002/jmv.21147.

PMID:
18360913
26.

Special considerations for glycolipids and their purification.

Smith DF, Prieto PA.

Curr Protoc Mol Biol. 2001 May;Chapter 17:Unit17.3. doi: 10.1002/0471142727.mb1703s22.

PMID:
18265160
27.

Intestinal toxicity induced by 5-fluorouracil in pigs: a new preclinical model.

Manzano M, Bueno P, Rueda R, Ramirez-Tortosa CL, Prieto PA, Lopez-Pedrosa JM.

Chemotherapy. 2007;53(5):344-55. Epub 2007 Sep 3.

PMID:
17785971
28.

In vitro and in vivo effects of soluble, monovalent globotriose on bacterial attachment and colonization.

Leach JL, Garber SA, Marcon AA, Prieto PA.

Antimicrob Agents Chemother. 2005 Sep;49(9):3842-6.

29.

Incorporating 3D body motions into large-sized freeform surface conceptual design.

Qin S, Wright DK, Kang J, Prieto PA.

Biomed Sci Instrum. 2005;41:271-6.

PMID:
15850117
30.

Transgenic animals and nutrition research.

Prieto PA, Kopchick JJ, Kelder B.

J Nutr Biochem. 1999 Dec;10(12):682-95.

PMID:
15539267
31.

Variability of human milk neutral oligosaccharides in a diverse population.

Erney RM, Malone WT, Skelding MB, Marcon AA, Kleman-Leyer KM, O'Ryan ML, Ruiz-Palacios G, Hilty MD, Pickering LK, Prieto PA.

J Pediatr Gastroenterol Nutr. 2000 Feb;30(2):181-92.

PMID:
10697138
32.
33.

Remodeling of mouse milk glycoconjugates by transgenic expression of a human glycosyltransferase.

Prieto PA, Mukerji P, Kelder B, Erney R, Gonzalez D, Yun JS, Smith DF, Moremen KW, Nardelli C, Pierce M, et al.

J Biol Chem. 1995 Dec 8;270(49):29515-9.

34.

A solid-phase assay for beta-1,4-galactosyltransferase activity in human serum using recombinant aequorin.

Zatta PF, Nyame K, Cormier MJ, Mattox SA, Prieto PA, Smith DF, Cummings RD.

Anal Biochem. 1991 Apr;194(1):185-91.

PMID:
1907813
36.

A new ganglioside in human meconium detected with antiserum against human milk sialyltetrasaccharide a.

Prieto PA, Smith DF.

Arch Biochem Biophys. 1986 Aug 15;249(1):243-53.

PMID:
3527068
37.
38.
39.

Supplemental Content

Loading ...
Support Center